<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04914481</url>
  </required_header>
  <id_info>
    <org_study_id>ATLAS TAVI</org_study_id>
    <nct_id>NCT04914481</nct_id>
  </id_info>
  <brief_title>Anatomic Stenosis Severity as a Prognostic Marker in Patients With Low-Flow Low-Gradient Aortic Stenosis Undergoing TAVI</brief_title>
  <acronym>ATLAS TAVI</acronym>
  <official_title>AnaTomic Stenosis Severity Derived From Computed Tomography as a Prognostic Marker in Patients With Low-flow Low-gradient Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut universitaire de cardiologie et de pneumologie de Québec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ATLAS TAVI Registry is a retrospective, investigator-initiated, multicenter registry&#xD;
      including patients, who underwent Transcatheter Aortic Valve Implantation (TAVI) for&#xD;
      classical or paradoxical low-flow, low-gradient aortic stenosis (LFLG AS) with available&#xD;
      non-contrast MSCT data on aortic valve calcification (AVC). The main objective of this study&#xD;
      is the assessment of outcome after TAVI according to AVC density severity in patients with&#xD;
      LFLG AS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aortic valve calcification (AVC) as assessed by MSCT is highly correlated with aortic&#xD;
      stenosis (AS) severity and, thus, has become an important tool for diagnosing severe AS,&#xD;
      especially in patients with low-flow low-gradient aortic stenosis (LFLG AS). Moreover, in&#xD;
      medically treated AS patients AVC is directly associated with poor prognosis. In contrast,&#xD;
      the prognostic benefit of eliminating AS by Transcatheter Aortic Valve Implantation (TAVI) in&#xD;
      patients with LFLG AS seems to be larger in patients with high AVC density (AVCd) compared to&#xD;
      those with low AVCd, at least in &quot;classical&quot; (low EF) LFLG AS. Hence, we hypothesize that&#xD;
      AVCd might be a valuable marker for treatment response among TAVI patients with LFLG AS, who&#xD;
      are known to suffer from poor outcome even after elimination of AS.&#xD;
&#xD;
      The multicentric ATLAS TAVI Registry of LFLG AS patients, who underwent TAVI, assesses the&#xD;
      impact of AVCd on outcome in these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Mortality</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of cardiovascular death, defined as death attributable to myocardial ischemia and infarction, heart failure, cardiac arrest because of other or unknown cause, or cerebrovascular accident.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalizations for congestive heart failure</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of new-onset or worsening signs and symptoms of heart failure that required urgent therapy and resulted in hospitalization, e.g. as assessed by patient interviews or hospital records.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Low-Flow, Low-Gradient Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Classical Low-Flow, Low-Gradient Aortic Stenosis</arm_group_label>
    <description>Classical Low-Flow, Low-Gradient Aortic Stenosis is defined as valve area &lt;1 cm2, mean gradient &lt;40 mmHg, ejection fraction &lt;50% and stroke volume index (SVi) ≤35 mL/m2 by resting transthoracic echocardiography. Dobutamine stress echocardiography is not mandatory for the definition of classical LFLG AS. All patients in this subgroup underwent TAVI and have available data on aortic valve calcification.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paradoxical Low-Flow, Low-Gradient Aortic Stenosis</arm_group_label>
    <description>Paradoxical Low-Flow, Low-Gradient Aortic Stenosis is defined as valve area &lt;1 cm2, mean gradient &lt;40 mmHg, ejection fraction ≥50% and SVi ≤35 mL/m2 by resting transthoracic echocardiography. All patients in this subgroup underwent TAVI and have available data on aortic valve calcification.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Gradient Aortic Stenosis (Control group)</arm_group_label>
    <description>High-Gradient Aortic Stenosis is defined as valve area &lt;1 cm2 and mean gradient &gt;40 mmHg by resting transthoracic echocardiography. All patients in this subgroup underwent TAVI. Data on aortic valve calcification is not mandatory for this control group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conservative treatment (Control group)</arm_group_label>
    <description>The subgroup includes all patients with (severe or non-severe) aortic stenosis, who underwent conservative treatment. Data on aortic valve calcification is not mandatory for this control group.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This is a retrospective, investigator-initiated, multicenter registry including patients,&#xD;
        who underwent TAVI for classical or paradoxical LFLG AS with available non-contrast MSCT&#xD;
        data on AVC. Furthermore, data will be gathered for the control groups of patients with&#xD;
        high-gradient AS, who underwent TAVI, and heart failure patients with concomitant AS, who&#xD;
        underwent medical treatment. MSCT data will not be mandatory for control groups.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥18 years&#xD;
&#xD;
          -  patient gave written informed consent for data acquisition and transfer&#xD;
&#xD;
          -  for LFLG AS: -- available non-contrast MSCT data on aortic valve calcification (AVC,&#xD;
             Agatston Units)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - LFLG AS without non-contrast MSCT data on AVC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Annick Clavel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Niklas Schofer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Heart and Vascular Center Hamburg, Hamburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sebastian Ludwig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Heart and Vascular Center Hamburg, Hamburg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Niklas Schofer, MD</last_name>
    <phone>+49-40-7410-0</phone>
    <email>n.schofer@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sebastian Ludwig, MD</last_name>
    <phone>+49-40-7410-0</phone>
    <email>se.ludwig@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walid Ben Ali, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval</name>
      <address>
        <city>Québec</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Annick Clavel, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Dahl, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augustin Coisne, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat - Claude-Bernard</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Urena Alcazar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won K Kim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Heart and Vascular Center Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niklas Schofer, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Sebastian Ludwig, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Heart Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Abdel-Wahab, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uri Landes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Centre</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas van Mieghem, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Dweck, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Cueff C, Serfaty JM, Cimadevilla C, Laissy JP, Himbert D, Tubach F, Duval X, Iung B, Enriquez-Sarano M, Vahanian A, Messika-Zeitoun D. Measurement of aortic valve calcification using multislice computed tomography: correlation with haemodynamic severity of aortic stenosis and clinical implication for patients with low ejection fraction. Heart. 2011 May;97(9):721-6. doi: 10.1136/hrt.2010.198853. Epub 2010 Aug 18.</citation>
    <PMID>20720250</PMID>
  </reference>
  <reference>
    <citation>Clavel MA, Messika-Zeitoun D, Pibarot P, Aggarwal SR, Malouf J, Araoz PA, Michelena HI, Cueff C, Larose E, Capoulade R, Vahanian A, Enriquez-Sarano M. The complex nature of discordant severe calcified aortic valve disease grading: new insights from combined Doppler echocardiographic and computed tomographic study. J Am Coll Cardiol. 2013 Dec 17;62(24):2329-38. doi: 10.1016/j.jacc.2013.08.1621. Epub 2013 Sep 24.</citation>
    <PMID>24076528</PMID>
  </reference>
  <reference>
    <citation>Clavel MA, Pibarot P, Messika-Zeitoun D, Capoulade R, Malouf J, Aggarval S, Araoz PA, Michelena HI, Cueff C, Larose E, Miller JD, Vahanian A, Enriquez-Sarano M. Impact of aortic valve calcification, as measured by MDCT, on survival in patients with aortic stenosis: results of an international registry study. J Am Coll Cardiol. 2014 Sep 23;64(12):1202-13. doi: 10.1016/j.jacc.2014.05.066.</citation>
    <PMID>25236511</PMID>
  </reference>
  <reference>
    <citation>Ludwig S, Goßling A, Waldschmidt L, Linder M, Bhadra OD, Voigtländer L, Schäfer A, Deuschl F, Schirmer J, Reichenspurner H, Blankenberg S, Schäfer U, Westermann D, Seiffert M, Conradi L, Schofer N. TAVR for low-flow, low-gradient aortic stenosis: Prognostic impact of aortic valve calcification. Am Heart J. 2020 Jul;225:138-148. doi: 10.1016/j.ahj.2020.03.013. Epub 2020 Apr 8.</citation>
    <PMID>32502877</PMID>
  </reference>
  <reference>
    <citation>Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017 Sep 21;38(36):2739-2791. doi: 10.1093/eurheartj/ehx391.</citation>
    <PMID>28886619</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Stenosis</keyword>
  <keyword>Low-Flow, Low-Gradient</keyword>
  <keyword>TAVI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

